News | December 30, 2025
Astal signs LoI with Immuna Therapeutics
Astal estimates the collaboration will generate incremental revenue of approximately Rs. 300 crore upon implementation
Astal estimates the collaboration will generate incremental revenue of approximately Rs. 300 crore upon implementation
Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials
CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development
The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas
The partnership also sets the stage for broader collaboration on rare disease treatments
TMS offers new hope to patients suffering from stroke, migraine, neuropathic pain, depression, and other disorders
INOVIO remains confident in the therapy’s benefits and intends to meet with the FDA to discuss maintaining eligibility under this pathway
Singlera and Pure Medical will team up with local universities, hospital networks, and national healthcare systems across Western Europe for research studies
NGD Infection Prevention was formed to scale the delivery of sequence-based transmission detection
The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38
Subscribe To Our Newsletter & Stay Updated
